Agenus | AGEN - Selling And Administration Expenses


Agenus reported $10.56M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.58B 316M Mar/2026
Agenus USD 10.56M 13.04M Dec/2025
Amgen USD 1.58B 354M Mar/2026
AstraZeneca USD 5.06B 455M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Celldex Therapeutics USD 11.45M 3.61M Mar/2026
CSL USD 1.23B 498M Dec/2025
Eli Lilly USD 2.93B 198M Mar/2026
Gilead Sciences USD 1.45B 326M Mar/2026
GlaxoSmithKline GBP 2.12B 558M Mar/2026
Glaxosmithkline GBP 3.56B 650.29M Dec/2025
Incyte USD 328.1M 62.31M Mar/2026
Intrexon USD 10.31M 41K Jun/2024
J&J USD 6.03B 719M Mar/2026
Jiangsu Hengrui CNY 2.81B 191.05M Mar/2026
Karyopharm Therapeutics USD 9.56M 17.63M Dec/2025
MacroGenics USD 7.94M 1.96M Dec/2025
Merck EUR 1.52B 80M Mar/2026
Merck USD 2.67B 180M Mar/2026
Northwest Biotherapeutics USD 7.07M 1.06M Sep/2025
Novartis USD 3.14B 296M Mar/2026
Novavax USD 25.53M 1.34M Dec/2025
Pfizer USD 2.92B 1.16B Mar/2026
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Veracyte USD 50.84M 7.53M Mar/2026